Cholinesterase Inhibitors: An Overview of their Mechanisms of Action
Alzheimer’s disease (AD) is a degenerative disorder of the CNS which will become a major health problem in the following decades. AD is associated with a decrease of cholinergic activity in the cortex and other brain regions. Of the different approaches to reversing the cholinergic deficit, the inhibition of acetylcholinesterase (AChE) seems to produce symptomatic improvements in clinical trials (Whitehouse, 1993).
KeywordsAChE Inhibitor Cholinergic Deficit Dimethylamino Ethyl Choline Ester Molecular Mechanic Force Field
Unable to display preview. Download preview PDF.
- Enz A, Amstutz R, Boddeke H, Gmelin G and Malanowsky J (1993): Brain selective inhibiton of acetylcholinesterase: a novel approach to therapy for Alzheimer’s disease. In: Cholinergic Function and Dysfunction, Progress in Brain Research Vol 98. Cuello AC, ed. Amsterdam, Elsevier Science Publisher, pp 431–438.CrossRefGoogle Scholar
- Spaldin V, Maddan S, Pool WF, Woolf TF and Park K (1994): The effect of enzyme inhibition on the metabolism and activation of tacrine by human liver microsomes. Br J Pharmac 38:15–22.Google Scholar
- Whitehouse PJ (1993): Cholinergic therapy in dementia. Acta Neurol Scand (Supp.) 149:42–45.Google Scholar